Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

Summer 8-2-2017

Malignant Hyperthermia
Brandon Kinnamon
brandon.kinnamon@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Musculoskeletal System Commons, and the Nursing Commons

Recommended Citation
Kinnamon, Brandon, "Malignant Hyperthermia" (2017). Nursing Student Class Projects (Formerly MSN).
205.
https://digitalcommons.otterbein.edu/stu_msn/205

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

Malignant Hyperthermia
Brandon Kinnamon, BSN, RN, CCRN
Otterbein University, Westerville, Ohio

Underlying Pathophysiology
•

•

Figure 1. Retrieved from
https://www.thinglink.com/scene/7052115329710817
29 on July 17, 2017.

•

•

•

The pathophysiological concept
selected for analysis is malignant
hyperthermia (MH).
Relevant in both the intensive
care unit and the operating room
while intubating patients or
inducing anesthesia.
Anesthetic inhalation agents like
halothane and the neuromuscular
blocking agent succinylcholine can
trigger a pathological response
involving intracellular calcium
resulting in hyper-metabolism
(Schneiderbanger, Johannsen,
Roewer & Schuster, 2014, p. 356357).
It is vital for anesthesia
professionals and critical care
nurses to recognize MH and act
quickly to limit rapid shifts of
electrolytes (Donnelly, 1994, p.
395).

When exposed to an environmental (heat stroke) or pharmacological
trigger, the mutation on RYR1 causes an uncontrolled release of
calcium from the sarcoplasmic reticulum in skeletal muscles
(Rosenberg, Pollock, Schiemann, Bulger & Stowell, 2015, p. 4).

•

The only other gene showing potential MH-causing mutation is
CACNA1S (Rosengerg, et al., 2015, p. 4).

•

The depolarizing muscle relaxant succinylcholine and volatile
anesthetics including halothane, isoflurane, enflurane, sevoflurane,
methoxyflurane, and desflurane can all trigger MH (Schneiderbanger,
et al., 2014, p. 356-357).

Introduction
•

Malignant hyperthermia is an autosomal dominant trait with a
mutation of the ryanodine receptor (RYR1) (Hirshey Dirksen, et al.,
2011, p. 1108).

•

•

•

Hallmark and earliest sign of malignant
hyperthermia is hypercapnia which can
be detected as an increase in end-tidal
carbon dioxide or EtCO2 (Lin et al.,
2014, p. 209).
Other major signs of MH include
muscle rigidity, tachycardia, tachypnea,
pyrexia, flushing followed by
peripheral mottling, cardiac
arrhythmias, hypotension,
rhabdomyolysis, and even
disseminated intravascular coagulation
(Brandom & Callahan, 2015, p.119).

•

•

Both metabolic and respiratory acidosis can
develop simultaneously resulting in a
profound acidotic state (Redmond, 2001, p.
261).
Symptoms can result in what appears to be
a comatose-state for the patient with
absent reflexes, fixed pupils, apnea, and
unconsciousness (Huether, McCance,
Brashers & Rote, 2008, p. 314).

-Hypercapnia
-Acidosis
-Rigidity -Hyperthermia

•

To compensate for the increased body temperature,
hyperventilation, vasodilation, and catecholamine release all occur
which lead to increased end-tidal carbon dioxide levels, flushing, and
tachycardia followed by cyanosis of the periphery (Brandom &
Callahan, 2015, p. 115).
If not halted this hypermetabolic state can lead to cardiac arrest,
hemorrhaging, and brain damage (Ali, Taguchi & Rosenberg, 2003).

•

•

•

When muscles become rigid they can no longer produce adenosine
triphosphate (ATP) which leads to cellular damage and leakage of
potassium, creatine kinase, and myoglobin from the muscle cells
(Brandom & Callahan, 2015, p. 115).
This leakage results in metabolic acidosis, cardiac arrhythmias, and
myoglobinuria (Brandom & Callahan, 2015, p. 115).

Implications
•

•

The uncontrolled release of calcium in the muscle leads to sustained
contraction causing a rise in exhaled carbon dioxide, the observable
muscle rigidity, and generates heat which leads to a dramatic rise in
body temperature (Seifert, Wahr, Pace, Cochrane & Bagnola, 2014, p.
189).

•

•

Signs and Symptoms of MH
•

•

Malignant hyperthermia is life-threatening and is associated with administration of
anesthetic agents and neuromuscular blocking agents.

•

It can occur rapidly, or slightly delayed, in any facility that administers the potential
triggering agents. This means that reactions can occur in the operating room (OR),
post anesthesia care unit (PACU), or the intensive care unit (ICU) (Seifert, et al.,
2014, p. 190).

Figure 2.
Retrieved from http://www.slideshare.net/larryide/capnography?next_slideshow=1 on July 17, 2017.

•

Without proper recognition, the affected patient can suffer dire consequences.
Cardiac arrest, disseminated intravascular coagulation, kidney failure, liver failure,
brain damage, and even death are potential outcomes if treatment is not initiated
and supportive care provided (Seifert, et al.,2014, p. 189).

•

This makes the pathophysiology of MH extremely significant and it is vital that the
anesthesia provider, PACU nurse or ICU nurse recognize the condition so it can be
treated.

The failure to monitor capnography and core
temperature puts patients experiencing MH
at an increased risk of death (Brandom &
Callahan, 2015, p. 119).
Once a patient develops MH the stoppage of
all triggering agents and immediate
administration of the skeletal muscle relaxant
dantrolene must begin (Lilley, Harrington &
Snyder, 2007, p. 190).
Dantrolene blocks the release of calcium
from the skeletal muscle cells and halts the
sustained contraction causing the
hypermetabolic state (Brandom & Callahan,
2015, p. 120).

Cooling the patient and correcting
hyperkalemia and acidosis are also frequently
necessary (Myers, 2009, p. 1135-1136).

•

Supportive care and dantrolene
administration will continue from the
operating room (OR) to the intensive care
unit (ICU) for at least forty-eight hours of
monitoring and continued care (Ali, et al.,
2003, p. 526).

•

Screening patients preoperatively can
prevent MH episodes before they happen.

•

A thorough individual (including muscular
pathologies) and family health history can
identify patients at risk for MH, since it can
be an inherited condition (Schneiderbanger,
et al., 2014, p. 360).

•

Muscular disorders including Central Core
Disease, Myotonic Muscular Dystrophy, and
King-Denborough syndrome are all conditions
predisposed to developing MH (Rosenberg,
et al., 2015, p. 3-4).

•

•

Conclusions
•

Malignant hyperthermia is a rare
and life-threatening condition which
is elicited by anesthetic agents used
during intubation and general
anesthesia (Cain, Riess, Gettrust &
Novalija, 2014, p. 301).

•

It is vital that nurses and anesthesia
providers know what to monitor and
what actions to take if a patient
develops MH.

•

•

Beta blockers and oxygen are also needed to
treat the tachycardia and hypoxia associated
with MH (Lilley et al., 2007, p. 171).

•

Figure 3. Retrieved from http://www.applewoodacupuncture.com/infrared-thermal-imaging/ on July 17,
2017.

Significance of Pathophysiology

Careful monitoring of end-tidal carbon
dioxide and core body temperature should be
conducted during surgical procedures
involving possible triggering agents (Lewis,
Dirksen, Heitkemper, Bucher & Camera,
2011, p. 363).

Testing can be performed to determine
susceptibility of MH in at-risk individuals with
the caffeine halothane contracture test
(CHCT) (Hirshey Dirksen, et al., 2011, p.
1112). During the test caffeine and
halothane are applied directly to muscle
bundles and will cause contracture at lower
concentrations in MH susceptible patients
(Hopkins, 2017, p. 323).
Families with the RYR1 mutation are referred
to the Malignant Hyperthermia Registry also
known as MHAUS for entry into the national
database (Myers, 2009, p. 1136).

•

•

Simulations can assist in preparing
personnel for a potential MH crisis
in a safe environment, and this
practice has been used regularly by
anesthesia professionals since 1994
(Cain et al., 2014, p. 302).
MHAUS has organized mock drills
with the funding help of professional
anesthesia associations and is a
valuable data bank for families and
anesthesia providers on malignant
hyperthermia (Brandom & Callahan,
2015, p. 124).
Future research on MH will likely
focus on genetics and the
phenotypic variability of RYR1related conditions (Hirshey Dirksen,
2011, p. 1110).
Accurately predicting which patients
are susceptible to MH will allow
providers to avoid possible
triggering agents while still
providing excellent anesthetic care
to those patients.
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